KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Sales (2017 - 2025)

Historic Return on Sales for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to 0.04%.

  • Biomarin Pharmaceutical's Return on Sales fell 1800.0% to 0.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17%, marking a year-over-year increase of 500.0%. This contributed to the annual value of 0.15% for FY2024, which is 800.0% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Return on Sales stood at 0.04%, which was down 1800.0% from 0.29% recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Return on Sales peaked at 0.29% during Q2 2025, and registered a low of 0.13% during Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Return on Sales value was 0.07% (recorded in 2023), while the average stood at 0.08%.
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -17400bps in 2021, then surged by 2000bps in 2022.
  • Biomarin Pharmaceutical's Return on Sales (Quarter) stood at 0.13% in 2021, then skyrocketed by 100bps to 0.0% in 2022, then skyrocketed by 6907bps to 0.03% in 2023, then skyrocketed by 430bps to 0.17% in 2024, then tumbled by -124bps to 0.04% in 2025.
  • Its Return on Sales stands at 0.04% for Q3 2025, versus 0.29% for Q2 2025 and 0.25% for Q1 2025.